X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Michelle Drozd

Michelle Drozd Michelle Drozd is a Deputy Vice President in the Policy and Research department at the PhRMA where she focuses on the evolving healthcare system and how to improve the use of medicines. Prior to joining PhRMA, she worked at Partners Healthcare and RTI International in Boston. Michelle spends her free time reading and doing house projects with her husband and two boys.

Recent Posts

Number of value-based contracts continues to rise

By Michelle Drozd  |    August 27, 2018
The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter –...   Read More

Reality check: Value-based contracts are good for patients

By Michelle Drozd  |    April 25, 2018
Biopharmaceutical companies are joining stakeholders across the health care system to pursue flexible ways to pay for medicines that focus on results, lower out-of-pocket costs and enable patients...   Read More

Clarity around anti-kickback statute needed to promote innovative payment arrangements

By Michelle Drozd  |    January 10, 2018
You may have recently read about how biopharmaceutical companies and insurers are working together to implement new approaches to paying for medicines, including through results-based contracts...   Read More

Modernizing FDA regulations to advance a value-driven health care system

By Michelle Drozd  |    June 8, 2017
A modern regulatory framework is the foundation of an innovative health care system that allows stakeholders to work together to deliver better outcomes for patients. To advance critical...   Read More

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

By Michelle Drozd  |    March 27, 2017
In recent years we have seen remarkable scientific breakthroughs in the discovery of new therapies to treat some of the most challenging diseases faced by patients. These groundbreaking medicines...   Read More

Stakeholders Agree: Modernize the legal framework to support move to value-driven health care

By Michelle Drozd  |    March 6, 2017
Modernizing certain laws and regulations to support the move to value-driven health care is an important step in moving our health care system forward. As part of PhRMA’s proactive policy...   Read More

ICYMI: Multi-stakeholder group recommended changes to support value-driven health care

By Michelle Drozd  |    September 14, 2016
As part of PhRMA’s efforts to explore policy solutions to promote value-driven health care, we recently participated in a forum convened by Deloitte and the Network for Excellence in Health...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates